TY - JOUR
T1 - Unveiling the potential of HS-1793
T2 - a review of its anticancer properties and therapeutic promise
AU - Capó, Xavier
AU - Jiménez-Garcia, Manuel
AU - Sharopov, Farukh
AU - Tsouh Fokou, Patrick Valere
AU - Martorell, Miquel
AU - Aldahish, Afaf Ahmed
AU - Pezzani, Raffaele
AU - Sharifi-Rad, Javad
AU - Calina, Daniela
N1 - Publisher Copyright:
© 2024 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2024
Y1 - 2024
N2 - HS-1793 is a novel derivative of resveratrol, a compound known for its numerous beneficial effects, including anticancer activity, anti-inflammatory response, antimicrobial, antiaging, anti-cardiovascular disease activity, neuroprotective activity, etc. Despite its wide and interesting properties, resveratrol suffers from a crucial flaw because it is low bioavailable. For this reason, many other derivatives were explored and among them, HS-1793 has caught the attention of researchers. HS-1793 is a synthetic derivative of resveratrol discovered in 2007 that has been shown to have anti-cancer and anti-inflammatory properties. In addition, the compound showed a positive profile in metabolic processes, with adequate pharmacokinetics and pharmacodynamics. This review highlights current research on HS-1793, evaluating in vitro and in vivo works and lays the foundation for novel explorative trials in human diseases.
AB - HS-1793 is a novel derivative of resveratrol, a compound known for its numerous beneficial effects, including anticancer activity, anti-inflammatory response, antimicrobial, antiaging, anti-cardiovascular disease activity, neuroprotective activity, etc. Despite its wide and interesting properties, resveratrol suffers from a crucial flaw because it is low bioavailable. For this reason, many other derivatives were explored and among them, HS-1793 has caught the attention of researchers. HS-1793 is a synthetic derivative of resveratrol discovered in 2007 that has been shown to have anti-cancer and anti-inflammatory properties. In addition, the compound showed a positive profile in metabolic processes, with adequate pharmacokinetics and pharmacodynamics. This review highlights current research on HS-1793, evaluating in vitro and in vivo works and lays the foundation for novel explorative trials in human diseases.
KW - HS-1793
KW - anticancer
KW - bioavailability
KW - cell models
KW - preclinical
KW - resveratrol
UR - https://www.scopus.com/pages/publications/85211220505
U2 - 10.1080/17568919.2024.2424150
DO - 10.1080/17568919.2024.2424150
M3 - Artículo de revisión
C2 - 39555577
AN - SCOPUS:85211220505
SN - 1756-8919
VL - 16
SP - 2301
EP - 2311
JO - Future Medicinal Chemistry
JF - Future Medicinal Chemistry
IS - 21
ER -